The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Open accessAbstract
Purpose: To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients. Patients and Methods: A database of conservative managed (conservative surgery followed by radiation) patients, in whom all three markers (estrogen receptor, progesterone receptor, and HER2/neu) were available, was reviewed. Patients were classified as triple negative if they tested negative for all three markers. Of 482 patients with all three markers available, 117 were classified as triple negative. Results: As of September 2005, with a median follow-up time of 7.9 years, of the 482 patients in the study, there have been 53 in-breast relapses, 10 nodal relapses, 77 distant relapses, and 69 deaths. At 5 years, the triple negative cohort had a poorer distant metastasis-free rate compared with the other subtypes (67% v 82%, respectively; P = .002). Triple negative subtype was an independent predictor of distant metastasis (hazard ratio = 2.14; 95% CI, 1.31 to 3.53; P = .002) and cause-specific survival (hazard ratio = 1.79; 95% CI, 1.03 to 3.22; P = .047). There was no significant difference in local control between the triple negative and other subtypes (83% v 83%, respectively). Of 99 BRCA-tested patients in this cohort, 10 had deleterious mutations in BRCA1, and seven had mutations in BRCA2. Of 10 BRCA1 patients, eight were triple negative, whereas only one of seven BRCA2 patients was triple negative (P < .001). Conclusion: Patients classified as triple negative have a poor prognosis. However, there was no evidence that these patients are at higher risk for local relapse after conservative surgery and radiation. Patients with BRCA1 mutations develop predominantly triple negative tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Research works printed but not linked: 3
- Charafe-Jauffret E, Ginestier C, Monville F, et al: How to best classify breast cancer: Conventional and novel classifications. Int J Oncol 27:1307,2005-1313, · doi:10.3892/ijo.27.5.1307
- 10.1016/0360-3016(88)90043-0 · DOI
- 10.1200/JCO.2002.07.137 · doi:10.1200/jco.2002.07.137
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., Bellon, J. R., Wong, J. S., Smith, B. L., & Harris, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4287 · Cited by 811
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 680
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3481-4 · Cited by 612
Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A. D., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C. G., Deng, N., et al. (2016) · Oncogene · doi:10.1038/onc.2015.381 · Cited by 580
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5565 · Cited by 568
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.012 · Cited by 495
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Melhem-Bertrandt, A., Chavez-MacGregor, M., Lei, X., Brown, E. N., Lee, R. T., Meric-Bernstam, F., Sood, A. K., Conzen, S. D., Hortobagyi, G. N., & Gonzalez-Angulo, A.-M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4441 · Cited by 464
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Bertucci, F., Finetti, P., & Birnbaum, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376134 · Cited by 394
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
Lowery, A. J., Kell, M. R., Glynn, R. W., Kerin, M. J., & Sweeney, K. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1891-6 · Cited by 389
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., & Foulkes, W. D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-134 · Cited by 365
Abdulkarim, B. S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., & Sabri, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4714 · Cited by 345
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Uematsu, T., Kasami, M., & Yuen, S. (2009) · Radiology · doi:10.1148/radiol.2503081054 · Cited by 344
Metzger-Filho, O., Sun, Z., Viale, G., Price, K. N., Crivellari, D., Snyder, R. D., Gelber, R. D., Castiglione-Gertsch, M., Coates, A. S., Goldhirsch, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1574 · Cited by 343
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Millar, E. K. A., Graham, P. H., O'Toole, S. A., McNeil, C. M., Browne, L., Morey, A. L., Eggleton, S., Beretov, J., Theocharous, C., Capp, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7075 · Cited by 314
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
Chen, X., Li, J., Gray, W. H., Lehmann, B. D., Bauer, J. A., Shyr, Y., & Pietenpol, J. A. (2012) · Cancer Informatics · doi:10.4137/cin.s9983 · Cited by 292
Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., & Lluch, A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.002 · Cited by 283
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment
Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018) · Radiology · doi:10.1148/radiol.2018172171 · Cited by 275
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Young, Sr., Pilarski, R. T., Donenberg, T., Shapiro, C., Hammond, L. S., Miller, J., Brooks, K. A., Cohen, S., Tenenholz, B., DeSai, D., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-86 · Cited by 273
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Pembrolizumab and atezolizumab in triple-negative breast cancer
Kwapisz, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02736-z · Cited by 271
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Taftaf, R., Liu, X., Singh, S., Jia, Y., Dashzeveg, N. K., Hoffmann, A. D., El-Shennawy, L., Ramos, E. K., Adorno-Cruz, V., Schuster, E. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25189-z · Cited by 261
Thike, A. A., Cheok, P. Y., Jara-Lazaro, A. R., Tan, B., Tan, P., & Tan, P. H. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.145 · Cited by 257
Miyashita, M., Sasano, H., Tamaki, K., Hirakawa, H., Takahashi, Y., Nakagawa, S., Watanabe, G., Tada, H., Suzuki, A., Ohuchi, N., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0632-x · Cited by 253
Scott, L. C., Mobley, L. R., Kuo, T., & Il’yasova, D. (2019) · Cancer · doi:10.1002/cncr.32207 · Cited by 165
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
The regulatory role of miRNAs on VDR in breast cancer
Singh, T., & Adams, B. D. (2017) · Transcription · doi:10.1080/21541264.2017.1317695 · Cited by 37
Platinum-based chemotherapy in triple-negative advanced breast cancer
Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3033-4 · Cited by 33
Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring
Kuzmin, E., Baker, T. M., Lesluyes, T., Monlong, J., Abe, K. T., Coelho, P. P., Schwartz, M., Del Corpo, J., Zou, D., Morin, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113988 · Cited by 20
Metadata
- Authors
- Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-12-20
- Volume
- 24
- Issue
- 36
- Pages
- 5652-5657
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138929540
- Cited by
- 1,084
- References
- 21
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.